论文部分内容阅读
目的评价重组组织型纤溶酶原激活剂(rt-PA)对≥75岁的高龄超早期脑梗死(发病后6h以内)的疗效及安全性。方法将60例急性脑梗死患者分为≥75岁的高龄组29例,<75岁的非高龄组31例,予以rt-PA0.9mg/kg静脉溶栓;对照组30例急性脑梗死患者,予以巴曲酶注射液治疗。采用CSS评分,分别于治疗前及治疗后6h、24h、3d、7d及14d记录神经功能缺损评分,并于治疗后30d及90d随访观察日常生活能力(ADL量表)。结果高龄及非高龄rt-PA治疗组神经功能改善无明显差异(P>0.05),但均优于对照组(P<0.05),治疗后并发症不随年龄增加而增多。结论 rt-PA治疗高龄的超早期脑梗死疗效肯定,安全性好。
Objective To evaluate the efficacy and safety of recombinant tissue plasminogen activator (rt-PA) in elderly patients with ultra-early cerebral infarction (within 6 hours after onset) of ≥75 years old. Methods A total of 60 patients with acute cerebral infarction were divided into two groups: 29 elderly patients ≥75 years old and 31 non-elderly patients <75 years old. Thirty-six patients with acute cerebral infarction were treated with rt-PA 0.9 mg / To batroxobin injection treatment. The scores of neurological deficits were recorded before treatment and at 6h, 24h, 3d, 7d and 14d after treatment respectively. The daily living ability (ADL scale) was observed at 30d and 90d after treatment. Results There was no significant difference in neurological function between the elderly and non-aged rt-PA group (P> 0.05), but both of them were superior to the control group (P <0.05). The complication did not increase with age. Conclusion rt-PA treatment of elderly patients with early-stage cerebral infarction positive, safe.